ArticleTechnology in cancer research & treatment
Artificial Intelligence Approaches for Predictive Biomarker Discovery in Non-Small Cell Lung Cancer.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionNon-small cell lung cancer (NSCLC) is the most prevalent and lethal subtype of lung cancer. Most patients are diagnosed at an advanced stage of the disease, resulting in a poor prognosis. Early treatment and clinical intervention for NSCLC following early diagnosis can improve patients' survival rate. It is of considerable significance to develop a more efficient and precise approach for identifying key genes and clinically pertinent biomarkers in NSCLC to enable its early diagnosis.MethodsAn interpretable two-stage analytical framework integrated with advanced artificial intelligence (AI) technology is proposed to enhance the accuracy of biological gene screening for NSCLC. Firstly, gene-level statistical features derived from the GSE19804,GSE30219 and GSE33532 datasets are standardized and dimensionally reduced via principal component analysis (PCA), which reveals two distinct linear distribution patterns of candidate genes in the PCA projection space. Subsequently, these candidate genes are validated using the TCGA and GEPIA platform by evaluating their differential expression profiles and associations with patient survival outcomes, with the goal of identifying robust predictive biomarkers.ResultsThrough AI-driven analytical pipelines, multiple tumor-associated genes are screened and confirmed to be correlated with NSCLC progression. Notably, ADGRD1 (Adhesion G Protein-Coupled Receptor D1) exhibits a close association with pulmonary physiological functions and may serve as a potential biomarker in the initiation and progression of NSCLC.ConclusionThe proposed method combines unsupervised structural discovery with cross-cohort clinical evidence to prioritize NSCLC biomarkers, providing critical support for early diagnosis, prognostic stratification, and biomarker-guided therapeutic strategies. Furthermore, the study provides technical support for biomarker discovery in other cancer types, and highlights the application value of integrating computational intelligence with oncology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.